DIRECT OBSERVATION OF THE QUATERNARY CONFORMATIONAL CHANGES INDUCED BY SUBSTRATE

直接观察底物引起的四元构象变化

基本信息

  • 批准号:
    7722147
  • 负责人:
  • 金额:
    $ 0.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project involves the study of a critical enzyme in metabolism, aspartate transcarbamoylase (ATCase). ATCase catalyzes the first step in pyrimidine nucleotide biosynthesis. The product of the reaction, carbamoyl aspartate is then converted into the pyrimidine nucleotides necessary for nucleic acid biosynthesis. ATCase has been identified as a target for anti-proliferation and anti-malarial drugs. Particularly important is that ATCase not only catalyzes the above reaction, but also controls the rate of pyrimidine biosynthesis. Regulation is achieved by a conformational switch from a low-activity T-state to a high-activity R-state. These two states have different quaternary conformations that can be easily distinguished by SAXS. By using a stopped flow mixer attached to the SAXS apparatus at SSRL we are ability to monitor the actual transition of the enzyme from the T to the R, and from the R to T, states induced by the natural substrates as well as potential drug candidates. For this project period we have two specific aims: (i) investigate the heterotropic interactions and homotropic cooperativity of ATCase using time-resolved SAXS, and (ii) monitor the cooperativity transition of ATCase from the T to the R state by time-resolved crystallography. The first specific aim is directed at determining the molecular level details of how ATCase is able to regulate pyrimidine nucleotide biosynthesis. The second specific aim will utilize the new capabilities of beamline 4-2 to obtain a time-lapsed record of the conformational changes that are required to convert the enzyme from the T to the R state by x-ray crystallography. This experiment will then be combined with other ongoing studies to determine by crystallography each of the steps in the catalytic and regulatory mechanisms of this important metabolic enzyme.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 本计画研究代谢中的关键酵素--天冬氨酸转氨甲酰酶(ATCase)。ATCase催化嘧啶核苷酸生物合成的第一步。反应产物氨基甲酰天冬氨酸随后转化为核酸生物合成所需的嘧啶核苷酸。ATCase已被确定为抗增殖和抗疟疾药物的靶点。特别重要的是,ATCase不仅催化上述反应,而且还控制嘧啶生物合成的速率。通过从低活性T状态到高活性R状态的构象转换来实现调节。这两种状态具有不同的四元构象,可以很容易地区分SAXS。通过在SSRL使用连接到SAXS装置的停流混合器,我们能够监测由天然底物以及潜在的候选药物诱导的酶从T到R以及从R到T状态的实际转变。在这个项目期间,我们有两个具体的目标:(i)调查异向性相互作用和同向性协同ATCase使用时间分辨SAXS,和(ii)监测协同ATCase从T到R状态的时间分辨晶体学。第一个具体目标是确定ATCase如何能够调节嘧啶核苷酸生物合成的分子水平细节。第二个具体目标将利用光束线4-2的新功能,通过X射线晶体学获得将酶从T状态转化为R状态所需的构象变化的时间推移记录。该实验将与其他正在进行的研究相结合,通过晶体学确定这种重要代谢酶的催化和调节机制中的每个步骤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EVAN R KANTROWITZ其他文献

EVAN R KANTROWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EVAN R KANTROWITZ', 18)}}的其他基金

DIRECT OBSERVATION OF THE QUATERNARY CONFORMATIONAL CHANGES INDUCED BY SUBSTRATE
直接观察底物引起的四元构象变化
  • 批准号:
    8362170
  • 财政年份:
    2011
  • 资助金额:
    $ 0.02万
  • 项目类别:
DIRECT OBSERVATION OF THE QUATERNARY CONFORMATIONAL CHANGES INDUCED BY SUBSTRATE
直接观察底物引起的四元构象变化
  • 批准号:
    8170121
  • 财政年份:
    2010
  • 资助金额:
    $ 0.02万
  • 项目类别:
DIRECT OBSERVATION OF THE QUATERNARY CONFORMATIONAL CHANGES INDUCED BY SUBSTRATE
直接观察底物引起的四元构象变化
  • 批准号:
    7954451
  • 财政年份:
    2009
  • 资助金额:
    $ 0.02万
  • 项目类别:
TIME EVOLUTION OF THE ALLOSTERIC TRANSITION OF ASPARTATE TRANSCARBAMOYLASE
天冬氨酸转氨甲酰酶变构转变的时间演化
  • 批准号:
    7597962
  • 财政年份:
    2007
  • 资助金额:
    $ 0.02万
  • 项目类别:
TIME EVOLUTION OF THE ALLOSTERIC TRANSITION OF ASPARTATE TRANSCARBAMOYLASE
天冬氨酸转氨甲酰酶变构转变的时间演化
  • 批准号:
    7370443
  • 财政年份:
    2006
  • 资助金额:
    $ 0.02万
  • 项目类别:
TIME EVOLUTION OF THE ALLOSTERIC TRANSITION OF ASPARTATE TRANSCARBAMOYLASE
天冬氨酸转氨甲酰酶变构转变的时间演化
  • 批准号:
    7180422
  • 财政年份:
    2005
  • 资助金额:
    $ 0.02万
  • 项目类别:
STRUCTURE OF A COBALT-SUBSTITUTED MUTANT OF ALKALINE PHOSPHASE
碱性磷酸相的钴取代突变体的结构
  • 批准号:
    6972664
  • 财政年份:
    2004
  • 资助金额:
    $ 0.02万
  • 项目类别:
TIME EVOLUTION OF ALLOSTERIC TRANSITION OF ASPARTATE TRANSCARBAMOYLASE
天冬氨酸转氨甲酰酶变构转变的时间演化
  • 批准号:
    6976330
  • 财政年份:
    2004
  • 资助金额:
    $ 0.02万
  • 项目类别:
STRUCT & FUNCT OF MUTANT VERSIONS OF ALKALINE PHOSPHATASE FROM ESCHERICHIA COLI
结构体
  • 批准号:
    6221083
  • 财政年份:
    1999
  • 资助金额:
    $ 0.02万
  • 项目类别:
STRUCTURE REFINEMENT OF MUTANT VERSIONS OF E COLI ASPARTATE TRANSCARBAMOYLASE
大肠杆菌天冬氨酸转氨甲酰酶突变体的结构精修
  • 批准号:
    6221094
  • 财政年份:
    1999
  • 资助金额:
    $ 0.02万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 0.02万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 0.02万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 0.02万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
    Operating Grants
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
    Studentship
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10663334
  • 财政年份:
    2022
  • 资助金额:
    $ 0.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了